| Heart Failure (HF) with normal ejection fraction | Diagnostic strategy. | Paulus W J (Amsterdam, NL) |
| Heart Failure (HF) with normal ejection fraction | Any specific treatment? | McMurray J J V (Glasgow, GB) |
| Hot Line I | Trial of Intensified (BNP-guided) versus standard (symptom-guided) Medical therapy in Elderly patients with Congestive Heart Failure (HF) TIME-CHF - Discussant. | Dickstein K (Stavanger, NO) |
| Hot Line I | Effects of n-3 PUFA in patients with symptomatic chronic Heart Failure (HF): the GISSI-HF results. | Tavazzi L (Pavia, IT) |
| Hot Line I | Effects of n-3 PUFA in patients with symptomatic chronic Heart Failure (HF): the GISSI-HF results - Discussant. | Komajda M (Paris, FR) |
| Hot Line I | Effects of statins in patients with symptomatic chronic Heart Failure (HF): the GISSI-HF results. | Tognoni G (Milan, IT) |
| Hot Line I | Effects of statins in patients with symptomatic chronic Heart Failure (HF): the GISSI-HF results - Discussant. | Poole-Wilson P A (London, GB) |
| Hot Line I | The TRANSCEND Study: a randomized placebo-controlled clinical trial evaluating the effects of telmisartan in high risk individuals without Heart Failure (HF) - Discussant. | Swedberg K (Goteborg, SE) |
| Fallacies from clinical trials | Heart Failure (HF). | Swedberg K (Goteborg, SE) |
| Moving from cure to palliation | Palliative care in Heart Failure (HF) patients. | Jaarsma T (Groningen, NL) |
| Evolving role of echo in Heart Failure (HF) | Evaluating patients with Heart Failure (HF) symptoms. | Pinto F J (Lisbon, PT) |
| Evolving role of echo in Heart Failure (HF) | Viability assessment - how to use the data. | Pierard L A (Liege, BE) |
| Evolving role of echo in Heart Failure (HF) | Role of contrast - assessing the microvasculature. | Senior R (Harrow, GB) |
| Evolving role of echo in Heart Failure (HF) | New approaches to left ventricular function. | Vannan M (Columbus, US) |
| Cardiac magnetic resonance imaging in Heart Failure (HF) | Case 1: value of echocardiography. | Pinto F J (Lisbon, PT) |
| Cardiac magnetic resonance imaging in Heart Failure (HF) | Discussion case 1. | Pinto F J (Lisbon, PT), A C Van Rossum (Amsterdam, NL) |
| Cardiac magnetic resonance imaging in Heart Failure (HF) | Case 2: value of cardiovascular magnetic resonance imaging. | Van Rossum A C (Amsterdam, NL) |
| The new ESC guidelines | Heart Failure (HF). | Dickstein K (Stavanger, NO) |
| 2008 ESC Heart Failure (HF) guidelines: what's new? | Diagnosis. | Poole-Wilson P A (London, GB) |
| 2008 ESC Heart Failure (HF) guidelines: what's new? | Drug therapy. | Boehm M (Homburg/Saar, DE) |
| 2008 ESC Heart Failure (HF) guidelines: what's new? | Devices. | Priori S G (Pavia, IT) |
| 2008 ESC Heart Failure (HF) guidelines: what's new? | Implementation. | Dickstein K (Stavanger, NO) |
| Clinical Trial Update II | Results from the BACH (Biomarkers in ACute Heart Failure (HF)) Trial. | Maisel A (San Diego, US) |
| Clinical Trial Update II | Results from the BACH (Biomarkers in ACute Heart Failure (HF)) Trial - Discussant. | McDonagh T A (London, GB) |
| Clinical Trial Update II | Changes in clinical, neurohormonal, electrolyte, renal, hematological and hepatic profiles during and after hospitalization for acute decompensated Heart Failure (HF): Analysis from the EVEREST trial. | Gheorghiade M (Chicago, US) |
| Clinical Trial Update II | Changes in clinical, neurohormonal, electrolyte, renal, hematological and hepatic profiles during and after hospitalization for acute decompensated Heart Failure (HF): Analysis from the EVEREST trial - Discussant. | Tendera M (Katowice, PL) |
| Clinical Trial Update III | Progressive reverse remodeling in patients with mild or asymptomatic Heart Failure (HF) with previous symptoms in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. | Linde C (Stockholm, SE) |
| Clinical Trial Update III | Progressive reverse remodeling in patients with mild or asymptomatic Heart Failure (HF) with previous symptoms in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. - Discussant. | Vardas P E (Heraklion, GR) |
| State of the Art - Novel therapies in Heart Failure (HF) | Prediction of survival in patients with cardiogenic shock and multiorgan failure treated with biventricular assist devices and the total artificial heart. | Potapov E V (Berlin, DE) |
| State of the Art - Novel therapies in Heart Failure (HF) | Twelve month follow-up of improvement of human infarcted heart muscle by intracoronary autologous mononuclear bone marrow cells in chronic coronary artery disease after myocardial infarction (IACT). | Koestering M (Duesseldorf, DE) |
| State of the Art - Novel therapies in Heart Failure (HF) | Effects of testosterone supplementation in elderly female patients with chronic Heart Failure (HF). | Caminiti G (Rome, IT) |
| State of the Art - Novel therapies in Heart Failure (HF) | Independent and additive influence of carvedilol and ivabradine on long-term prognosis in patients with severe chronic Heart Failure (HF) of ischemic origin. | Tumasyan L R (Yerevan, AM) |
| State of the Art - Novel therapies in Heart Failure (HF) | State of the Art - Building on the success of Heart Failure (HF) therapies. | Pfeffer M (Boston, US) |
| Hot Line I | Trial of Intensified (BNP-guided) versus standard (symptom-guided) Medical therapy in Elderly patients with Congestive Heart Failure TIME-CHF. | H P Brunner-La Rocca (Basel, CH) |